Skip to main content
Publication date
2017 05
Authors
Ilander, M Olsson-Stromberg, U Schlums, H Guilhot, J Bruck, O Lahteenmaki, H Kasanen, T Koskenvesa, P Soderlund, S Hoglund, M Markevarn, B Sjalander, A Lotfi, K Dreimane, A Lubking, A Holm, E Bjoreman, M Lehmann, S Stenke, L Ohm, L Gedde-Dahl, T Majeed, W Ehrencrona, H Koskela, S Saussele, S Mahon, FX Porkka, K Hjorth-Hansen, H Bryceson, YT Richter, J Mustjoki, S
Author KI Usernames
Bryceson, YT|yenbry Lehmann, S|sorleh Schlums, H|heschl Stenke, L|leiste
Pubmed ID
27890936
Journal
Leukemia
Doctype
Article
KI Connection
Medel
Mesh SV
Cytokiner Dasatinib Fall-kontrollstudier Imatinibmesilat Leukemi, myeloid, kronisk, BCR-ABL positiv Lymfocytantal Lymfocytsubset Människa Mördarceller, naturliga Proteinkinashämmare Pyrimidiner Sjukdomsfri överlevnad Upphävande av behandling
Mesh EN
Case-Control Studies Cytokines Dasatinib Disease-Free Survival Imatinib Mesylate Killer Cells, Natural Leukemia, Myelogenous, Chronic, BCR-ABL Positive Lymphocyte Count Lymphocyte Subsets Protein Kinase Inhibitors Pyrimidines Withholding Treatment
First date
2017-05-14T10:59:55.804Z